iBio
Using artificial intelligence to efficiently and consistently delivers antibody candidates against difficult targets.
Launch date
Employees
Market cap
$16.6m
Enterprise valuation
$29m (Public information from Sep 2024)
Share price
$1.9 IBIO
Newark New Jersey (HQ)
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 1.6m | 2.4m | 2.4m | - | <1m | 2.0m | - |
| % growth | (19 %) | 45 % | 1 % | - | - | 7900 % | - |
| EBITDA | (11.7m) | (31.0m) | (45.7m) | (27.7m) | - | - | - |
| % EBITDA margin | (717 %) | (1306 %) | (1918 %) | - | - | - | - |
| Profit | (16.4m) | (23.2m) | (50.3m) | (65.0m) | - | - | - |
| % profit margin | (1004 %) | (979 %) | (2111 %) | - | - | - | - |
| EV / revenue | 160.4x | 138.8x | 24.2x | - | 679.6x | 8.5x | - |
| EV / EBITDA | -22.4x | -10.6x | -1.3x | -0.4x | - | - | - |
| R&D budget | 3.2m | 10.0m | 17.7m | 10.3m | - | - | - |
| R&D % of revenue | 196 % | 421 % | 744 % | - | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | N/A | IPO | |
| N/A | $3.0m | Post IPO Debt | |
| N/A | $7.1m | Post IPO Debt | |
| N/A | $2.2m | Post IPO Debt | |
* | $22.4m | Post IPO Debt | |
* | N/A | $3.5m | Post IPO Equity |
* | N/A | $4.5m | Post IPO Equity |
* | N/A | $15.1m | Private Placement VC |
| Total Funding | $15.1m | ||
Related Content
Recent News about iBio
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by iBio
Edit
ACQUISITION by iBio Sep 2022